Comparison of amplification enzymes for Hepatitis C virus quasispecies analysis

Virology Journal

Volumn 2, Issue , 2005, Pages

  Polyak, Stephen J ^a   Sullivan, Daniel G ^a   Austin, Michael A ^a   Dai, James Y ^a   Shuhart, Margaret C ^a   Lindsay, Karen L ^c   Bonkovsky, Herbert L ^d   Di Bisceglie, Adrian M ^e   Lee, William M ^f   Morishima, Chihiro ^a,b   Gretch, David R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH FIDELITY 2 POLYMERASE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TAQ POLYMERASE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS GLYCOPROTEIN;

ACCURACY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME ANALYSIS; FEMALE; GENE AMPLIFICATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HETERODUPLEX ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MALE; MOLECULAR EVOLUTION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SPECIES DIVERSITY; SUPERINFECTION; VIRUS ENVELOPE; VIRUS GENE;

ADULT; ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; FEMALE; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TAQ POLYMERASE;

HEPATITIS C VIRUS;

EID: 21844467196     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-2-41     Document Type: Article

References (35)

1. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J: Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992, 66(5):3225-3229.
2. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K: Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 1991, 175(1):220-228.
3. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, Saracco G, Choo QL, Houghton M: Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991, 180(2):842-848.
4. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH: Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994, 91(16):7792-7796.
5. Higashi Y, Kakumu S, Yoshioka K, Wakita T, Mizokami M, Ohba K, Ito Y, Ishikawa T, Takayanagi M, Nagai Y: Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology 1993, 197(2):659-668.
6. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotohno K: Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 1993, 67(7):3923-3930.
7. Okamoto H, Kojima M, Okada S, Yoshizawa H, Iizuka H, Tanaka T, Muchmore EE, Peterson DA, Ito Y, Mishiro S: Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992, 190(2):894-899.
8. van Doorn LJ, Capriles I, Maertens G, DeLeys R, Murray K, Kos T, Schellekens H, Quint W: Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol 1995, 69(2):773-778.
9. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA, et al.: Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 1992, 89(8):3468-3472.
10. Ziebert A, Schreier E, Roggendorf M: Antibodies in human sera specific to hypervariable region 1 of Hepatitis C virus can block viral attachment. Virology 1995, 208:653-661.
11. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL, Perkins JD, Corey L: Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 1996, 70(11):7622-7631.
12. Sullivan DG, Wilson JJ, Carithers RL, Perkins JD, Gretch DR: Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. Journal of Virology 1998, 72(12):10036-10043.
13. Wilson JJ, Polyak SJ, Day TD, Gretch DR: Characterization of simple and complex hepatitis C virus quasispecies by heteroduplex gel shift analysis: correlation with nucleotide sequencing. J Gen Virol 1995, 76:1763-1771.
14. Lyra AC, Fan X, Lang DM, Yusim K, Ramrakhiani S, Brunt EM, Korber B, Perelson AS, Di Bisceglie AM: Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 2002, 123(5):1485-1493.
15. Fan X, Di Bisceglie AM: Diversification of hypervariable region 1 of hepatitis C virus after liver transplantation. J Med Virol 2003, 70(2):212-218.
16. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL: Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy. J Virol 1999, 73(4):2938-2946.
17. Pawlotsky JM: Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 2003, 7(1):45-66.
18. Mao Q, Ray SC, Laeyendecker O, Ticehurst JR, Strathdee SA, Vlahov D, Thomas DL: Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. J Virol 2001, 75(7):3259-3267.
19. Babik JM, Holodniy M: Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. J Virol 2003, 77(3):1940-1950.
20. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, et al.: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126(4):1015-1023.
21. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, et al.: Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004, 25(5):472-492.
22. Forns X, Bukh J: The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin Liver Dis 1999, 3(4):693-716. vii
23. Delwart EL, Shpaer EG, Louwagie J, McCutchan FE, Grez M, Rubsamen WH, Mullins JI: Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science 1993, 262(5137):1257-1261.
24. Delwart EL, Sheppard HW, Walker BD, Goudsmit J, Mullins JI: Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 1994, 68(10):6672-6683.
25. Polyak SJ, Faulkner G, Carithers RL, Corey L, Gretch DR: Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to Interferon therapy. J Infect Dis 1997, 175(5):1101-1107.
26. Polyak SJ, McArdle S, Liu SL, Sullivan DG, Chung MJ, Hofgartner WT, Carithers RL, McMahon BJ, Mullins JI, Corey L, et al.: Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998, 72(5):4288-4296.
27. Gerotto M, Sullivan DC, Polyak SJ, Chemello L, Cavalletto L, Pontisso P, Alberti A, Gretch DR: Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C. Journal Of Virology 1999, 73(9):7241-7247.
28. Gerotto M, Dal P-F, Sullivan DG, Chemello L, Cavalletto L, Polyak SJ, Pontisso P, Gretch DR, Alberti A: Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferonalpha. J Viral Hepatitis 1999, 6(5):367-372.
29. Sullivan DG, Kim SS, Wilson JJ, Stehman-Breen C, Gretch DR: Investigating hepatitis C virus heterogeneity in a high prevalence setting using heteroduplex tracking analysis. J Virol Methods 2001, 96(1):5-16.
30. Smith DB, McAllister J, Casino C, Simmonds P: Virus 'quasispecies': Making a mountain out of a molehill? Journal Of General Virology 1997, 78:1511-1519.
31. Mullan B, Kenny-Walsh E, Collins JK, Shanahan F, Fanning LJ: Inferred hepatitis C virus quasispecies diversity is influenced by choice of DNA polymerase in reverse transcriptase-polymerase chain reactions. Anal Biochem 2001, 289(2):137-146.
32. Nousbaum J, Polyak SJ, Ray SC, Sullivan DG, Larson AM, Carithers RL Jr, Gretch DR: Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000, 74(19):9028-9038.
33. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM: Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 2001, 75(12):5703-5710.
34. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, Di Bisceglie AM, Lindsay KL, Malet PF, Chang M, Gretch DR, et al.: Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 2005, 41(3):617-625.
35. Saldanha J, Lelie N, Heath A: Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 1999, 76(3):149-158.